Join CST and Reaction Biology for Discovery Dialogues: Cell-Based Assays in Early Drug Development

29 September 2025 | 2:00 - 6:00 pm CEST |Heidelberg

Join scientific experts for an engaging afternoon on 29 September 2025, from 2:00 to 6:00 PM CEST at Heidelberg Technology Park  – Business Development Center. The meeting will convene experts offering diverse perspectives on early-stage drug discovery, with a focus on antisense therapeutics, targeted protein degradation, and precision oncology.

Limited spots available—register now to secure your place!

 

Featured Speakers:

Dr. Christina Theisgen

Christina Theisgen, PhD

Senior Global Product Trainer

Cell Signaling Technology, The Netherlands

Title: Hallmarks of Antibody Validation to De-Risk Drug Discovery

Dr. Jan Ehlert

Jan Ehlert, PhD

Head of Cellular Pharmacology,

Reaction Biology Europe GmbH, Germany

Title: Preclinal Drug Development Targeting Phosphatase WIP1A

 

Dr. Johanna Huchting

Johanna Huchting, PhD

Post Doc, Discovery Research ScreeningPort

Fraunhofer Institute, Germany

Title: Degrader Discovery Tools for Application in TPD Screening

Dr. Matthias Klugmann

Matthias Klugmann, PhD

Associate Director, Gene Therapy

Boehringer Ingelheim Pharma GmbH & Co, KG, Germany

Title: Towards Next Generation AAV Gene Therapy @ Boehringer Ingelheim

 

Saskia Biskup, PhD

Saskia Biskup, PhD

Chief Executive Officer,

CeGat GmbH, Germany

Title: From Precision Diagnostics to Precision Treatment in Brain Cancer

Dr. Andre Maaske

Andre Maaske, PhD

Scientist, Immuno Oncology

Secarna Pharmaceuticals, Germany

Title: Anti-Tumor Activity of Neuropilin-1 Specific Antisense Oligonucleotides as Monotherapy and in Combination with Checkpoint Inhibitors